The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden hours per response: 4.00

1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	None	Entity Type	
0001621221	REACTIVE MEDICAL INC.		X Corporation	
Name of Issuer	KNIGHT KN	OX DEVELOPMENT CORP.	Limited Partnership	
ARTELO BIOSCIENCES, INC.			H	
Jurisdiction of Incorporation/Orga	anization		Limited Liability Company	
NEVADA			General Partnership	
Year of Incorporation/Organization	on		Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Speci	fv Year)		Other (Specify)	
	, , , ,			
Yet to Be Formed				
2. Principal Place of Business a	and Contact Information			
Name of Issuer				
ARTELO BIOSCIENCES, INC.				
Street Address 1		Street Address 2		
505 Lomas Santa Fe		Suite 160		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer	
Solana Beach	CALIFORNIA	92075	858-925-7049	
B. Related Persons				
Last Name	First Name		Middle Name	
Gorgas	Gregory		D.	
Street Address 1	Street Address 2			
c/o Artelo Biosciences, Inc.	505 Lomas Santa Fe	e, Suite 160		
City	State/Province/Co	untry	ZIP/PostalCode	
Solana Beach	CALIFORNIA		92075	
Relationship: \overline{X} Executive Office	x X Director Promoter			
Clarification of Response (if Nece	essary):			
Last Name	First Name		Middle Name	
Matsui	Connie			
Street Address 1	Street Address 2			
c/o Artelo Biosciences, Inc.	505 Lomas Santa Fe	e, Suite 160		
City	State/Province/Co	untry	ZIP/PostalCode	
Solana Beach	CALIFORNIA		92075	
Relationship: Executive Officer	X Director Promoter			
Clarification of Response (if Nece	ssary):			
Last Name	First Name		Middle Name	
Blayney	Douglas			
Street Address 1	Street Address 2			
c/o Artelo Biosciences, Inc.	505 Lomas Santa Fe	e. Suite 160		
City	State/Province/Co		ZIP/PostalCode	
Solana Beach	CALIFORNIA	• • •	92075	

Clarification of Response (if Necessary):

Street Address 1	Street Address 2		
c/o Artelo Biosciences, Inc.	505 Lomas Santa Fe, Suite 160		
City	State/Province/Country	ZIP/PostalCode	
Solana Beach	CALIFORNIA	92075	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	y):		
Last Name	First Name	Middle Name	
Emanuele	R.	Martin	
Street Address 1	Street Address 2		
c/o Artelo Biosciences, Inc.	505 Lomas Santa Fe, Suite 160		
City	State/Province/Country	ZIP/PostalCode	
Solana Beach	CALIFORNIA	92075	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	у):		
Last Name	First Name	Middle Name	
Favorito	Tamara	A .	
Street Address 1	Street Address 2		
c/o Artelo Biosciences, Inc.	505 Lomas Santa Fe, Suite 160		
City	State/Province/Country	ZIP/PostalCode	
Solana Beach	CALIFORNIA	92075	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	y):		
Last Name	First Name	Middle Name	
Reyes	Gregory	R.	
Street Address 1	Street Address 2		
c/o Artelo Biosciences, Inc.	505 Lomas Santa Fe, Suite 160		
City	State/Province/Country	ZIP/PostalCode	
Solana Beach	CALIFORNIA	92075	
Relationship: Executive Officer X	Director Promoter		
Clarification of Response (if Necessar	y):		
	F:	Middle Name	
Last Name	First Name		
Last Name Spring	First Name Mark		
Spring	Mark Street Address 2 505 Lomas Santa Fe, Suite 160		
Spring Street Address 1	Mark Street Address 2	ZIP/PostalCode	
Spring Street Address 1 c/o Artelo Biosciences, Inc.	Mark Street Address 2 505 Lomas Santa Fe, Suite 160	ZIP/PostalCode 92075	
Spring Street Address 1 c/o Artelo Biosciences, Inc. City	Mark Street Address 2 505 Lomas Santa Fe, Suite 160 State/Province/Country CALIFORNIA		
Spring Street Address 1 c/o Artelo Biosciences, Inc. City Solana Beach	Mark Street Address 2 505 Lomas Santa Fe, Suite 160 State/Province/Country CALIFORNIA Director Promoter		

Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	Computers
Investing		
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes	Ц	Tourism & Travel Services
Other Banking & Financial Services	Construction	
	REITS & Finance	Other Travel
	Residential	Other
Business Services		
Energy	Other Real Estate	
Coal Mining		
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net /	Asset Value Range
No Revenues		e Net Asset Value
\$1 - \$1,000,000	\$1 - \$5,000,0	00
\$1,000,001 - \$5,000,000	\$5,000,001 -	\$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001	- \$50,000,000
\$25,000,001 - \$100,000,000	\$50,000,001	- \$100,000,000
Over \$100,000,000	Over \$100,00	00,000
X Decline to Disclose	Decline to Dis	sclose
Not Applicable	Not Applicabl	e
	-	

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company	Act Section 3(c)			
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)			
Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)			
Rule 504 (b)(1)(ii)					
片	Section 3(c)(3)	Section 3(c)(11)			
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)			
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)			
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)			
	Section 3(c)(7)				
7. Type of Filing					
X New Notice Date of First Sale 2025-10-28 First Sale Y	et to Occur				
Amendment					
8. Duration of Offering					
Described by the second this offering to be between the second					
Does the Issuer intend this offering to last more than one year	ar? Yes X No				
9. Type(s) of Securities Offered (select all that apply)					
П- ч	Пъ				
☐ Equity		poled Investment Fund Interests			
X Debt					
X Option, Warrant or Other Right to Acquire Another Securit	· <u></u>	ineral Property Securities			
Security to be Acquired Upon Exercise of Option, Warrant Acquire Security	of Other Right to	ther (describe)			
10. Business Combination Transaction					
Is this offering being made in connection with a business cor or exchange offer?	nbination transaction, su	ch as a merger, acquisition Yes X No			
Clarification of Response (if Necessary):					
11. Minimum Investment					
Minimum investment accepted from any outside investor \$0	USD				
12. Sales Compensation					
Recipient	Paciniant CI	RD Number X None			
<u> </u>					
(Associated) Broker or Dealer X None		(Associated) Broker or Dealer CRD Number X None			
Street Address 1 City		Street Address 2 State/Province/Country ZIP/Postal C			
State(s) of Solicitation (select all that apply)	c) of Solicitation (solect all that apply)		// ootal oodo		
Check "All States" or check individual States	Foreign/no	511-05			
13. Offering and Sales Amounts					
Total Offering Amount \$3,718,121 USD or Indefinite					
Total Amount Sold \$3,718,121 USD					
Total Remaining to be Sold \$0 USD or Indefinite					
Clarification of Response (if Necessary):					
\$3,027,966.32 upon the exercise of warrants; \$690,154.69 converti	ble debt				
14. Investors					
☐ Select if securities in the offering have been or may be so	old to persons who do no	t qualify as accredited investors, and enter t	he number of		
such non-accredited investors who already have invested		t quality as assistanted investors, and effect			
Regardless of whether securities in the offering have bee total number of investors who already have invested in the		ons who do not qualify as accredited investo	ors, enter the 14		

15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$0 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission

Terms of Submission

notice.

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
ARTELO BIOSCIENCES, INC.	/s/ Gregory D. Gorgas	Gregory D. Gorgas	President & CEO	2025-11-10

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.